Hamburg’s hammer falls on Avastin; breast cancer use revoked
This article was originally published in Scrip
Executive Summary
The hammer came down on 18 November for Avastin's (bevacizumab) use in HER2-negative metastatic breast cancer (MBC), with the US FDA declaring the drug was not shown to be safe or effective in treating patients with the disease – revoking that indication for the Genentech cancer medicine.